These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12538066)

  • 21. Lodixanol inhibits exogenous surfactant therapy in rats with acute respiratory distress syndrome.
    Kesecioglu J; Schultz MJ; Haitsma JJ; den Heeten GJ; Lachmann B
    Eur Respir J; 2002 May; 19(5):820-6. PubMed ID: 12030719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of airway wall motion on surfactant delivery.
    Halpern D; Bull JL; Grotberg JB
    J Biomech Eng; 2004 Aug; 126(4):410-9. PubMed ID: 15543858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the interaction of particulate delivery systems with lung surfactant.
    Wiedmann TS
    Methods Mol Med; 2003; 75():755-69. PubMed ID: 12407777
    [No Abstract]   [Full Text] [Related]  

  • 24. The fate of exogenous surfactant in neonates with respiratory distress syndrome.
    Hallman M; Merritt TA; Bry K
    Clin Pharmacokinet; 1994 Mar; 26(3):215-32. PubMed ID: 8194284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosing and delivery of a recombinant surfactant in lung-injured adult sheep.
    Lewis J; McCaig L; Häfner D; Spragg R; Veldhuizen R; Kerr C
    Am J Respir Crit Care Med; 1999 Mar; 159(3):741-7. PubMed ID: 10051245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A theoretical study of surfactant and liquid delivery into the lung.
    Halpern D; Jensen OE; Grotberg JB
    J Appl Physiol (1985); 1998 Jul; 85(1):333-52. PubMed ID: 9655794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights into exogenous surfactant as a carrier of pulmonary therapeutics.
    Baer B; Souza LMP; Pimentel AS; Veldhuizen RAW
    Biochem Pharmacol; 2019 Jun; 164():64-73. PubMed ID: 30928674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of endotracheally instilled surfactant protein SP-C in lung-lavaged rabbits.
    Oetomo SB; de Ley L; Curstedt T; ter Haar JG; Schoots C; Wildevuur CR; Okken A
    Pediatr Res; 1991 Feb; 29(2):178-81. PubMed ID: 2014155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelium damage and protection during reopening of occluded airways in a physiologic microfluidic pulmonary airway model.
    Tavana H; Zamankhan P; Christensen PJ; Grotberg JB; Takayama S
    Biomed Microdevices; 2011 Aug; 13(4):731-42. PubMed ID: 21487664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges.
    Ruge CA; Kirch J; Lehr CM
    Lancet Respir Med; 2013 Jul; 1(5):402-13. PubMed ID: 24429205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of a second dose of exogenous surfactant in rabbits with severe respiratory failure.
    Plötz FB; Stevens H; Heikamp A; Oetomo SB
    Pediatr Res; 1995 Apr; 37(4 Pt 1):476-81. PubMed ID: 7596688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tensiometric and Phase Domain Behavior of Lung Surfactant on Mucus-like Viscoelastic Hydrogels.
    Schenck DM; Fiegel J
    ACS Appl Mater Interfaces; 2016 Mar; 8(9):5917-28. PubMed ID: 26894883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exogenous surfactant as a drug delivery agent.
    Haitsma JJ; Lachmann U; Lachmann B
    Adv Drug Deliv Rev; 2001 Apr; 47(2-3):197-207. PubMed ID: 11311992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of rheology and surface tension of airway surface liquid: a review of clinical relevance and measurement techniques.
    Chen Z; Zhong M; Luo Y; Deng L; Hu Z; Song Y
    Respir Res; 2019 Dec; 20(1):274. PubMed ID: 31801520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicochemical effects enhance surfactant transport in pulsatile motion of a semi-infinite bubble.
    Pillert JE; Gaver DP
    Biophys J; 2009 Jan; 96(1):312-27. PubMed ID: 18849416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aerosolized versus instilled exogenous surfactant in a nonuniform pattern of lung injury.
    Lewis JF; McCaig L
    Am Rev Respir Dis; 1993 Nov; 148(5):1187-93. PubMed ID: 8239152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carrier-based strategies for targeting protein and peptide drugs to the lungs.
    Cryan SA
    AAPS J; 2005 Mar; 7(1):E20-41. PubMed ID: 16146340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery.
    Das SC; Stewart PJ
    Int J Pharm; 2016 Dec; 514(2):465-474. PubMed ID: 27321111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
    Wang YB; Watts AB; Peters JI; Williams RO
    Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets.
    Balaraman V; Meister J; Ku TL; Sood SL; Tam E; Killeen J; Uyehara CF; Egan E; Easa D
    Am J Respir Crit Care Med; 1998 Jul; 158(1):12-7. PubMed ID: 9655700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.